Encoded is creating one-time, disease-modifying gene therapies for pediatric CNS disorders with its cell-selective targeting and regulation platform.
Location: United States
Employees: 51-200
Total raised: $514M
Founded date: 2014
Investors 6
| Date | Name | Website |
| 10.03.2024 | RONA Holdi... | ronaholdin... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| 07.09.2020 | Meritech C... | meritechca... |
| - | Biobrit | biobrit.co... |
| - | Menlo Vent... | menlovc.co... |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.09.2026 | Series F | $275M | Venrock |
| 22.07.2020 | Series D | $135M | - |
| 26.06.2019 | Series C | $104M | - |
Mentions in press and media 10
| Date | Title | Description |
| 09.09.2026 | Encoded Therapeutics Inks $275 Million in Series F | SOUTH SAN FRANCISCO, CA, Encoded Therapeutics, a clinical-stage biotechnology company, announced the close of a $275 million financing. >> Click here for more funding data on Encoded Therapeutics >> To export Encoded Therapeuti... |
| 29.07.2026 | Dravet Syndrome Hijacks Brain’s Immune Alarm to Sustain Seizures, Study Finds | By James Whitaker Published: Jul 29 2026, 2:19 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 27.07.2020 | Encoded Therapeutics Closes $135 Million In Series D Funding | Precision gene therapy company Encoded Therapeutics announced it has raised $135 million in an oversubscribed Series D round of funding Precision gene therapy company Encoded Therapeutics, Inc. (Encoded) announced it has raised $135 million... |
| 24.07.2020 | StartUPDATES: New developments from healthcare startups | Eikonoklastes, a preclinical biopharmaceutical company developing next-generation tissue factor immunotherapies for triple-negative breast cancer, has closed an oversubscribed seed funding round. Working with The Ohio State University Corpo... |
| 23.07.2020 | Encoded Therapeutics Raises $135M in Series D Financing | Encoded Therapeutics, Inc., a South Francisco, Calif.-based precision gene therapy company, raised $135m in Series D financing. The round was led by GV (formerly Google Ventures) with participation from Matrix Capital Management, ARCH Ventu... |
| 22.07.2020 | Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome and Advance Preclinical Pipeline of Gene Therapies for Debilitating Neurologic... | SOUTH SAN FRANCISCO, Calif., July 22, 2020 /PRNewswire/ -- Encoded Therapeutics, Inc. (Encoded), a precision gene therapy company, today announced it has raised $135 million in an oversubscribed Series D financing. The company also announce... |
| 25.06.2020 | Illumina’s accelerator has an impressive 93 percent follow-on funding rate — here’re its latest picks | Since its launch in 1998, Illumina and its genetic analysis toolkits and services have become an essential component of the new biological manufacturing and therapeutic development industries that have emerged in the last 25 years. And for ... |
| 26.06.2019 | Encoded Therapeutics Raises $104M in Series C Financing | Encoded Therapeutics, Inc., a South San Francisco, Calif.-based precision gene therapy company, raised $104m in Series C financing. Backers included existing shareholders Venrock, ARCH Venture Partners, Matrix Capital Management, Illumina V... |
| - | StartUPDATES: New developments from healthcare startups | HealCo’s Health System Without Walls (HSWOW) is healthcare’s tele-hybrid solution. Simply put, we’ve merged traditional brick-and-mortar office visits with telemedicine. Here’s how it works: Telemedicine solves many problems in outpatient c... |
| - | Encoded Therapeutics | - |